Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
YY Janjigian, CG Azzoli, LM Krug, LK Pereira… - Clinical cancer …, 2011 - AACR
… with lung cancer … in phase III study as initial treatment in patients with lung adenocarcinoma
and primary EGFR mutations. Data in mice with L858R and T790M erlotinib-resistant lung …
and primary EGFR mutations. Data in mice with L858R and T790M erlotinib-resistant lung …
Experience with erlotinib in the treatment of non-small cell lung cancer
L Landi, F Cappuzzo - Therapeutic Advances in Respiratory …, 2015 - journals.sagepub.com
… The ATLAS trial was a phase III study comparing maintenance erlotinib plus bevacizumab
versus bevacizumab alone in patients with NSCLC without progressive disease after four …
versus bevacizumab alone in patients with NSCLC without progressive disease after four …
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - ascopubs.org
… -naive patients with unresectable stage III or IV NSCLC; age … erlotinib combined with GC
was not significantly inferior to GC alone, with the exception of increased incidences of grade 3…
was not significantly inferior to GC alone, with the exception of increased incidences of grade 3…
… Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in …
C Gridelli, C Butts, F Ciardiello, R Feld, C Gallo… - Clinical lung cancer, 2008 - Elsevier
… Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small
cell lung cancer: the Tarceva Lung Cancer … TRIBUTE: a phase III trial of erlotinib …
cell lung cancer: the Tarceva Lung Cancer … TRIBUTE: a phase III trial of erlotinib …
A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan… - Cancer …, 2006 - Wiley Online Library
… , the previous Phase I study demonstrated adequate absorption of oral high-dose erlotinib, …
The Phase I/II trial reported here was designed to evaluate the tolerability and efficacy of …
The Phase I/II trial reported here was designed to evaluate the tolerability and efficacy of …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The lancet …, 2014 - thelancet.com
… Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic … Because
of this limitation, we undertook this phase 2 trial to examine the combination of erlotinib and …
of this limitation, we undertook this phase 2 trial to examine the combination of erlotinib and …
Activity and safety of erlotinib as second-and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
D Rossi, D Dennetta, M Ugolini, V Catalano… - Targeted …, 2010 - Springer
… cancer [2, 3]. Prospective data in the elderly population derived especially from two Italian
phase III … Europe for the treatment of recurrent NSCLC are erlotinib [9] and, recently, gefitinib (…
phase III … Europe for the treatment of recurrent NSCLC are erlotinib [9] and, recently, gefitinib (…
Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
… , and head and neck squamous cell cancer, respectively, show favorable activity compared
… Phase III trials with erlotinib in non-small cell lung cancer and pancreatic cancer are in …
… Phase III trials with erlotinib in non-small cell lung cancer and pancreatic cancer are in …
[HTML][HTML] Erlotinib as second‑or third‑line treatment in elderly patients with advanced non‑small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)
M Miyawaki, K Naoki, S Yoda… - Molecular and …, 2017 - spandidos-publications.com
… Patients eligible for this study were aged ≥70 years and had confirmed stage III or IV or
postoperative recurrent NSCLC. The patients were previously treated with 1 or 2 chemotherapy …
postoperative recurrent NSCLC. The patients were previously treated with 1 or 2 chemotherapy …
[HTML][HTML] … versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung …
… test in patients with advanced squamous cell carcinoma of the lung treated with second-line
afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017; 109: 101-108 …
afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017; 109: 101-108 …